# A Phase 1, First Time in Humans Study of NST-1024

> **NCT04630366** · PHASE1 · COMPLETED · sponsor: **NorthSea Therapeutics B.V.** · enrollment: 96 (actual)

## Conditions studied

- Hypertriglyceridemia

## Interventions

- **DRUG:** NST-1024
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04630366
- **Lead sponsor:** NorthSea Therapeutics B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-27
- **Primary completion:** 2022-06-20
- **Final completion:** 2022-06-20
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2022-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04630366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04630366, "A Phase 1, First Time in Humans Study of NST-1024". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04630366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*